| Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled … L Kappos, JS Wolinsky, G Giovannoni, DL Arnold, Q Wang, C Bernasconi, ... JAMA neurology 77 (9), 1132-1140, 2020 | 343 | 2020 |
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies PR Ho, H Koendgen, N Campbell, B Haddock, S Richman, IH Chang The Lancet Neurology 16 (11), 925-933, 2017 | 307 | 2017 |
| Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the … JS Wolinsky, DL Arnold, B Brochet, HP Hartung, X Montalban, ... The Lancet Neurology 19 (12), 998-1009, 2020 | 134 | 2020 |
| The dynamical response properties of neocortical neurons to temporally modulated noisy inputs in vitro H Köndgen, C Geisler, S Fusi, XJ Wang, HR Lüscher, M Giugliano Cerebral cortex 18 (9), 2086-2097, 2008 | 128 | 2008 |
| Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension SL Hauser, L Kappos, DL Arnold, A Bar-Or, B Brochet, RT Naismith, ... Neurology 95 (13), e1854-e1867, 2020 | 119 | 2020 |
| Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses G Giovannoni, G Cutter, MP Sormani, S Belachew, R Hyde, H Koendgen, ... Multiple sclerosis and related disorders 12, 70-78, 2017 | 118 | 2017 |
| Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies L Mayer, L Kappos, MK Racke, K Rammohan, A Traboulsee, SL Hauser, ... Multiple sclerosis and related disorders 30, 236-243, 2019 | 103 | 2019 |
| Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study L Kappos, H Butzkueven, H Wiendl, T Spelman, F Pellegrini, Y Chen, ... Multiple Sclerosis Journal 24 (7), 963-973, 2018 | 99 | 2018 |
| Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis SL Hauser, L Kappos, X Montalban, L Craveiro, C Chognot, R Hughes, ... Neurology 97 (16), e1546-e1559, 2021 | 97 | 2021 |
| COVID-19 in ocrelizumab-treated people with multiple sclerosis R Hughes, L Whitley, K Fitovski, HM Schneble, E Muros, A Sauter, ... Multiple sclerosis and related disorders 49, 102725, 2021 | 73 | 2021 |
| COVID-19 in persons with multiple sclerosis treated with ocrelizumab–a pharmacovigilance case series R Hughes, R Pedotti, H Koendgen Multiple sclerosis and related disorders 42, 102192, 2020 | 56 | 2020 |
| Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis F Barkhof, L Kappos, JS Wolinsky, DKB Li, A Bar-Or, HP Hartung, ... Neurology 93 (19), e1778-e1786, 2019 | 50 | 2019 |
| Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions T Derfuss, MS Weber, R Hughes, Q Wang, A Sauter, H Koendgen, ... Mult scler 25 (Suppl 2), 20-1, 2019 | 39 | 2019 |
| Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis SL Hauser, L Kappos, X Montalban, R Hughes, H Koendgen, ... Multiple sclerosis and related disorders 26, 264, 2018 | 25 | 2018 |
| Cases reported as progressive multifocal leukoencephalopathy in Ocrelizumab-treated patients with multiple sclerosis DB Clifford, A Gass, N Richert, C Tornatore, P Vermersch, R Hughes, ... Poster session presented at the European Committee for Treatment and …, 2019 | 23 | 2019 |
| Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay D Campagnolo, Q Dong, L Lee, PR Ho, D Amarante, H Koendgen Journal of neurovirology 22, 880-881, 2016 | 23 | 2016 |
| Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment A Bar-Or, GA Thanei, CT Harp, AH Cross, SL Hauser, J Kuhle, D Leppert, ... ECTRIMS Online Library 9, 2019 | 21 | 2019 |
| Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting M Trojano, H Butzkueven, L Kappos, H Wiendl, T Spelman, F Pellegrini, ... Multiple sclerosis and related disorders 24, 11-19, 2018 | 20 | 2018 |
| Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the … A Bar-Or, GA Thanei, C Harp, C Bernasconi, U Bonati, AH Cross, ... EBioMedicine 93, 2023 | 17 | 2023 |
| Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial AL Mammen, AA Amato, MM Dimachkie, H Chinoy, Y Hussain, JB Lilleker, ... The Lancet Rheumatology 5 (2), e67-e76, 2023 | 17 | 2023 |
Ludwig KapposUniversity Hospital BaselVerified email at uhbs.ch
